Quotient AliveDx and Global Marketing Services sign distribution agreements for Pakistan - Marketscreener.com
| 4171 Stock | TWD 27.80 0.30 1.07% |
Slightly above 62% of GeneReach Biotechnology's investor base is looking to short. The analysis of current outlook of investing in GeneReach Biotechnology suggests that many traders are alarmed regarding GeneReach Biotechnology's prospects. GeneReach Biotechnology's investing sentiment can be driven by a variety of factors including economic data, GeneReach Biotechnology's earnings reports, geopolitical events, and overall market trends.
GeneReach Biotechnology stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of GeneReach daily returns and investor perception about the current price of GeneReach Biotechnology as well as its diversification or hedging effects on your existing portfolios.
GeneReach |
Quotient AliveDx and Global Marketing Services sign distribution agreements for Pakistan Marketscreener.com
Read at news.google.com
 |
GeneReach Biotechnology Fundamental Analysis
We analyze GeneReach Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneReach Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneReach Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
GeneReach Biotechnology is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
GeneReach Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GeneReach Biotechnology stock to make a market-neutral strategy. Peer analysis of GeneReach Biotechnology could also be used in its relative valuation, which is a method of valuing GeneReach Biotechnology by comparing valuation metrics with similar companies.
Peers
GeneReach Biotechnology Related Equities
| 4162 | PharmaEngine | 5.02 | ||||
| 6712 | Ever Supreme | 1.73 | ||||
| 4142 | Adimmune Corp | 1.51 | ||||
| 4147 | TaiMed Biologics | 1.49 | ||||
| 1760 | Panion BF | 0.85 | ||||
| 6589 | EirGenix | 0.41 | ||||
| 6547 | Medigen Vaccine | 0.14 | ||||
| 4174 | OBI Pharma | 0.52 | ||||
| 4743 | Oneness Biotech | 2.67 | ||||
| 6541 | Tanvex BioPharma | 2.78 |
Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.